Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Eichhorst

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Cancers|April 3, 2021
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome ResistanceMoritz Fürstenau, Barbara Eichhorst
Acta Haematologica|February 25, 2021
Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 PandemicPetra Langerbeins, Barbara Eichhorst
Best Practice & Research. Clinical Haematology|August 21, 2007
Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL)Barbara Eichhorst, Michael Hallek
Hematology. American Society of Hematology. Education Program|December 4, 2016
Prognostication of chronic lymphocytic leukemia in the era of new agentsBarbara Eichhorst, Michael Hallek
Leukemia & Lymphoma|February 7, 2009
Treatment of elderly patients with chronic lymphocytic leukemiaBarbara Eichhorst, Valentin Goede, Michael Hallek
Oncology Research and Treatment|February 19, 2016
State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic LeukemiaPaula Cramer, Michael Hallek, Barbara Eichhorst
Leukemia & Lymphoma|April 29, 2014
Emerging therapies for refractory chronic lymphocytic leukemiaNadine Kutsch, Michael Hallek, Barbara Eichhorst
Hematology. American Society of Hematology. Education Program|December 7, 2019
Relapsed disease and aspects of undetectable MRD and treatment discontinuationBarbara Eichhorst, Moritz Fürstenau, Michael Hallek
Journal of Geriatric Oncology|August 6, 2016
New treatment approaches in CLL: Challenges and opportunities in the elderlyBarbara Eichhorst, Michael Hallek, Valentin Goede
Haematologica|October 6, 2019
Sequential and combination treatments with novel agents in chronic lymphocytic leukemiaMoritz Fürstenau, Michael Hallek, Barbara Eichhorst
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Cancers|April 3, 2021
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome ResistanceMoritz Fürstenau, Barbara Eichhorst
Acta Haematologica|February 25, 2021
Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 PandemicPetra Langerbeins, Barbara Eichhorst
Best Practice & Research. Clinical Haematology|August 21, 2007
Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL)Barbara Eichhorst, Michael Hallek
Hematology. American Society of Hematology. Education Program|December 4, 2016
Prognostication of chronic lymphocytic leukemia in the era of new agentsBarbara Eichhorst, Michael Hallek
Leukemia & Lymphoma|February 7, 2009
Treatment of elderly patients with chronic lymphocytic leukemiaBarbara Eichhorst, Valentin Goede, Michael Hallek
Oncology Research and Treatment|February 19, 2016
State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic LeukemiaPaula Cramer, Michael Hallek, Barbara Eichhorst
Leukemia & Lymphoma|April 29, 2014
Emerging therapies for refractory chronic lymphocytic leukemiaNadine Kutsch, Michael Hallek, Barbara Eichhorst
Hematology. American Society of Hematology. Education Program|December 7, 2019
Relapsed disease and aspects of undetectable MRD and treatment discontinuationBarbara Eichhorst, Moritz Fürstenau, Michael Hallek
Journal of Geriatric Oncology|August 6, 2016
New treatment approaches in CLL: Challenges and opportunities in the elderlyBarbara Eichhorst, Michael Hallek, Valentin Goede
Haematologica|October 6, 2019
Sequential and combination treatments with novel agents in chronic lymphocytic leukemiaMoritz Fürstenau, Michael Hallek, Barbara Eichhorst
Pageof 12